Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6420042 | 0.90 | P2RY1 (0.49) | P2RY1POLBGAAPTGDR2KMT2A | |
| SCHEMBL6420214 | 0.90 | MCL1 (0.41) | P2RY1POLBL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6419684 | 0.83 | TP53 (0.37) | P2RY1POLBGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL6420125 | 0.79 | MCL1 (0.43) | P2RY1POLBPTGDR2ALDH1A1MEN1 | |
| SCHEMBL6419648 | 0.79 | MCL1 (0.41) | P2RY1POLBPTGDR2ALDH1A1MEN1 | |
| SCHEMBL6421823 | 0.77 | MCL1 (0.41) | P2RY1POLBSMN1; SMN2TP53MEN1 | |
| SCHEMBL6420083 | 0.77 | MCL1 (0.43) | P2RY1L3MBTL1MEN1MAPTKMT2A | |
| SCHEMBL6423932 | 0.77 | MCL1 (0.38) | POLBPTGDR2TP53MAPT | |
| SCHEMBL6423538 | 0.75 | SIRT3 (0.41) | POLBGAAALDH1A1SMN1; SMN2SIRT3 | |
| SCHEMBL6418769 | 0.75 | MCL1 (0.39) | P2RY1ALDH1A1SMN1; SMN2TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930104-B2 | Heterocyclic derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20040157850-A1 | Novel heterocyclic derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1382598-A1 | NOVEL HETEROCYCLIC DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157850-A1 | Novel heterocyclic derivatives | APP, BACE1, PSEN1 | P2RY1 256/4885POLB 4822/4885GAA 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.